Creative Medical receives notice of allowance for prevention, treatment of T1D

Creative Medical (CELZ) Technology announced that it has received a Notice of Allowance from the United States Patent and Trademark Office, USPTO, for a U.S. patent application titled, “Prevention and/or Treatment of Type 1 Diabetes, T1D, by Augmentation of Myeloid Suppressor Cell Activity.” Once granted, the patent will be in effect until at least 2040. The patent allows a broad cell-based immunotherapy approach to treating Type 1 diabetes using the ImmCelzTM product, which includes the supercharged T regulatory cells using the Company’s proprietary cell-free solutions. This program has been validated using cells from patients with Type 1 Diabetes.